ReviewFrontiers in immunology2015
Involvement of CD8(+) T Cells in Multiple Sclerosis.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 115 citations in OpenAlex.
- A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet haemocyanin to evaluate adaptive immune responses in man.British journal of clinical pharmacology · 2021Trial
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.JAMA neurology · 2017Trial
- Immune Cells as Mediators Between Gut Microbiota and Multiple Sclerosis: Insights From Mendelian Randomization.Immunity, inflammation and disease · 2026Article
- Mesenchymal stromal cells and neuroinflammation: a multimodal approach to neuroprotection and future therapeutic horizons.Translational neurodegeneration · 2026Review
- Anti-MOG IgG in EAE models clinical aspects of pediatric MOGAD.Frontiers in immunology · 2026Article
- Enhancement of CD8Journal of translational autoimmunity · 2025Article
- The Role of Cobalamin in Multiple Sclerosis: An Update.Inflammation · 2025Review
- Myelin-reactive CD8Journal of neuroinflammation · 2025Article
- Memory Cells in Infection and Autoimmunity: Mechanisms, Functions, and Therapeutic Implications.Vaccines · 2025Review
- Regnase-1 in cDC1 controls T cell priming and shapes the dynamics of experimental autoimmune encephalomyelitis.Frontiers in immunology · 2025Article
- Specific imaging of CD8 + T-Cell dynamics with a nanobody radiotracer against human CD8β.European journal of nuclear medicine and molecular imaging · 2024Article
- Osteoarthritis in People with Multiple Sclerosis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Current Knowledge about CD3International journal of molecular sciences · 2024Review
- The brain cytokine orchestra in multiple sclerosis: from neuroinflammation to synaptopathology.Molecular brain · 2024Review
- Inflammation and heterogeneity in synucleinopathies.Frontiers in immunology · 2024Review
- Transcriptional rewiring in CD8Frontiers in immunology · 2024Review
- Inflammation as common link to progressive neurological diseases.Archives of toxicology · 2024Review
- Imbalance of Innate and Adaptive Immunity in Esophageal Achalasia.Journal of neurogastroenterology and motility · 2023Article
- Review
- Immune Regulatory Functions of Macrophages and Microglia in Central Nervous System Diseases.International journal of molecular sciences · 2023Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by focal demyelination patches associated with inflammatory infiltrates containing T lymphocytes. For decades, CD4(+) T cells have been recognized as playing a major role in the disease, especially in animal models, which has led to the development of several therapies. However, interest has recently developed in the involvement of CD8(+) T cells in MS following the analysis of infiltrating T cells in human brain lesions. A broad range of evidence now suggests that the pathological role of this T cell subset in MS may have been underestimated. In this review, we summarize the literature implicating CD8(+) T cells in the pathophysiology of MS. We present data from studies in the fields of genetics, anatomopathology and immunology, mainly in humans but also in animal models of MS. Altogether, this strongly suggests that CD8(+) T cells may be major effectors in the disease process, and that the development of treatments specifically targeting this subset would be germane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.